Ameriprise
CABA icon

Ameriprise’s Cabaletta Bio CABA Stock Holding History

Ameriprise’s Portfolio CABA Stock Details CABA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.58M Buy
+828,145
New +$2.72M ﹤0.01% 2944

Other funds holding CABA

Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
CAM
Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return

Ameriprise's CABA Position: Q2 2026 in Review

Ameriprise opened a new position in Cabaletta Bio (CABA) in Q2 2026: 828,145 shares worth $2.58M. The stake represents ﹤0.01% of the portfolio and ranks #2944 among its holdings.

140 funds tracked by Wall St. Rank hold CABA as of Q2 2026.

  • Ameriprise held 828,145 shares of Cabaletta Bio worth $2.58M as of Q2 2026.
  • Cabaletta Bio was a new Ameriprise position in Q2 2026.
  • Cabaletta Bio made up ﹤0.01% of Ameriprise's portfolio in Q2 2026, its #2944 holding.
  • 140 funds tracked by Wall St. Rank held Cabaletta Bio as of Q2 2026.

Based on Ameriprise's 13F filing for Q2 2026, filed 14 Aug 2026.